E
E.J. Gane
Researcher at University of Auckland
Publications - 185
Citations - 6864
E.J. Gane is an academic researcher from University of Auckland. The author has contributed to research in topics: Ribavirin & Sofosbuvir. The author has an hindex of 34, co-authored 185 publications receiving 5639 citations. Previous affiliations of E.J. Gane include Queen Mary University of London & Auckland City Hospital.
Papers
More filters
Journal ArticleDOI
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
Nucleotide Polymerase Inhibitor So fos bu vir plus Ribavirin for Hepatitis C
E.J. Gane,Catherine A.M. Stedman,Robert H. Hyland,Xiao Ding,Evguenia S. Svarovskaia,William T. Symonds,R. Hindes,M.M. Berrey +7 more
TL;DR: Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection, and the rate of sustained virologic response 24 weeks after therapy is reported.
Journal ArticleDOI
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore,E.J. Gane,Jorg Taubel,Justin Kao,Marianna Fontana,Michael L. Maitland,Jessica Seitzer,Daniel J. Corporal O'connell,Kathryn R. Walsh,Wood Kristy M,Jonathan Phillips,Yuanxin Xu,Adam Amaral,Adam P. Boyd,Jeffrey Cehelsky,Mark D. McKee,Andrew Schiermeier,Olivier Harari,Andrew J. Murphy,Christos A. Kyratsous,Brian Zambrowicz,Randy Soltys,David E. Gutstein,John P. Leonard,Laura Sepp-Lorenzino,David Lebwohl +25 more
TL;DR: Transthyretin amyloidosis (ATTR) is a life-threatening disease characterized by progressive accumulation of misfolded transthyrein (TTR) protein in tissus as mentioned in this paper.
Journal ArticleDOI
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie,Curtis Cooper,Michael S. Saag,Kimberly A. Workowski,Peter Ruane,William J. Towner,Kristen M. Marks,Anne F Luetkemeyer,Rachel Baden,Rachel Baden,Paul E. Sax,E.J. Gane,Jorge Santana-Bagur,Luisa M. Stamm,Jenny C. Yang,Polina German,Hadas Dvory-Sobol,Liyun Ni,Phillip S. Pang,John G. McHutchison,Catherine A.M. Stedman,Javier O Morales-Ramirez,Norbert Bräu,Norbert Bräu,Dushyantha Jayaweera,Amy E. Colson,Pablo Tebas,David Wong,Douglas T. Dieterich,Mark S. Sulkowski +29 more
TL;DR: Ledipasvir and sofosbuvir as a single fixed-dose combination for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4.
Journal ArticleDOI
Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study
TL;DR: Poor nutritional status with protein depletion and reduced muscle function was a common finding, particularly in men, and was not related to the presence of hypermetabolism or reduced energy and protein intakes, while the greater conservation of protein stores in women than in men warrants further investigation.